Literature DB >> 32739566

Regulatory effect of Zuojin Pill on correlation with gut microbiota and Treg cells in DSS-induced colitis.

Bu-Gao Zhou1, Fu-Chun Liu2, Hai-Mei Zhao3, Xiao-Yun Zhang4, Hai-Yan Wang5, Duan-Yong Liu6.   

Abstract

ETHNOPHARMACOLOGICAL RELEVANCE: As a classic prescription and commercial Chinese patent medicine, Zuojin Pill (ZJP) has been used to treat ulcerative colitis (UC) effectively for many years. However, its mechanism of action remains unclear. AIM OF THE STUDY:
METHODS: Mice with dextran-sulfate-sodium-induced colitis were treated with ZJP for 7 d. In the present study, the therapeutic effect of ZJP was evaluated by macroscopic and microscopic observation; regulatory T (Treg) cells and their subsets were analyzed by flow cytometry; and the composition of gut microbiota was tested by 16S rRNA analysis. Activation of the phosphoinostide 3-kinase (PI3K)/Akt signaling pathway was observed by western blotting.
RESULTS: The pathological damage was attenuated and expression of proinflammatory cytokines was decreased. While the diversity of intestinal microflora was regulated, the relative abundance of Actinobacteria, and Sphingobacteriia was modified. Meanwhile, the level of CD4+CD25+Foxp3+ and PD-L1+ Treg cells improved. These changes maintained a positive correlation which was analyzed statistically. Our results also showed that ZJP inhibited activation of the PI3K/Akt signaling pathway.
CONCLUSIONS: ZJP regulates crosstalk between intestinal microflora and Treg cells to attenuate experimental colitis via the PI3K/Akt signaling pathway.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Gut microbiota; PI3K/Akt signaling pathway; Treg cells; Ulcerative colitis; Zuojin pill

Year:  2020        PMID: 32739566     DOI: 10.1016/j.jep.2020.113211

Source DB:  PubMed          Journal:  J Ethnopharmacol        ISSN: 0378-8741            Impact factor:   4.360


  7 in total

Review 1.  Inflammatory bowel disease: an overview of Chinese herbal medicine formula-based treatment.

Authors:  Shuo Yuan; Qi Wang; Jiao Li; Jia-Chen Xue; You Li; Huan Meng; Xiao-Ting Hou; Ji-Xing Nan; Qing-Gao Zhang
Journal:  Chin Med       Date:  2022-06-18       Impact factor: 4.546

Review 2.  Phenolic Compounds Impact on Rheumatoid Arthritis, Inflammatory Bowel Disease and Microbiota Modulation.

Authors:  Rosa Direito; João Rocha; Bruno Sepodes; Maria Eduardo-Figueira
Journal:  Pharmaceutics       Date:  2021-01-22       Impact factor: 6.321

3.  Sishen Pill Maintained Colonic Mucosal Barrier Integrity to Treat Ulcerative Colitis via Rho/ROCK Signaling Pathway.

Authors:  Xiao-Yun Zhang; Hai-Mei Zhao; Yi Liu; Xiu-Yun Lu; Yan-Zhen Li; Qi-Hong Pan; Hai-Yan Wang; Wei Ge; Duan-Yong Liu
Journal:  Evid Based Complement Alternat Med       Date:  2021-12-09       Impact factor: 2.629

Review 4.  Based on Network Pharmacology to Explore the Potential Bioactive Compounds and Mechanisms of Zuojin Pill for the Treatment of Ulcerative Colitis.

Authors:  Ying Wei; Sichen Ren; Ruilin Wang; Manyi Jing; Honghong Liu; Min Wang; Hongtao Song; Yanling Zhao
Journal:  Evid Based Complement Alternat Med       Date:  2021-08-26       Impact factor: 2.629

5.  Toxicity and toxicokinetics of the ethanol extract of Zuojin formula.

Authors:  Shuo Wang; Tao Zhang; Xiaoyan Liu; Zheng Yang; Ludi Li; Danping Shan; Yadong Gao; Yingzi Li; Yanying Li; Youbo Zhang; Qi Wang
Journal:  BMC Complement Med Ther       Date:  2022-08-15

6.  Jatrorrhizine Alleviates DSS-Induced Ulcerative Colitis by Regulating the Intestinal Barrier Function and Inhibiting TLR4/MyD88/NF-κB Signaling Pathway.

Authors:  Shengqi Niu; Manyi Jing; Jianxia Wen; Shizhang Wei; Haotian Li; Xing Li; Xiao Ma; Yanling Zhao
Journal:  Evid Based Complement Alternat Med       Date:  2022-09-19       Impact factor: 2.650

7.  Metabolomic Study of Zuojin Pill in Relieving 1-Methyl-3-nitro-1-nitrosoguanidine-Induced Chronic Atrophic Gastritis.

Authors:  Yuling Tong; Manyi Jing; Xu Zhao; Honghong Liu; Shizhang Wei; Ruisheng Li; Xia Liu; Min Wang; Hongtao Song; Yanling Zhao
Journal:  Evid Based Complement Alternat Med       Date:  2021-12-17       Impact factor: 2.629

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.